* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Anxiety Treatment
Survey
Document related concepts
Transcript
Zizzer Zazzer Zuzz Anxiety Treatment Good News ! E. Jane Garland MD, FRCPC Clinical Professor, UBC Head, Mood & Anxiety Disorders Clinic, BC’s Children’s Hospital Key challenges in anxiety Rx • Anxiety is “normal” • Disorders are prevalent (10-15%) • Disorders are chronic & recurrent • The good news! Medication effect size greater in anxiety than in depression • Functional improvement is greater with CBT but it is hard to “take” Case Example • 10 year old boy • Anxious parents; shy child, past excessive separation anxiety; allergies, food sensitivities, intermittent asthma • c/o stomach aches sending him home from school, also gets SOB when upset • Mom having to take time off work to pick him up and stay home with him Symptoms • Chronic bedtime resistance and initial insomnia; some cosleeping • c/o stomach aches in am, rarely vomits (retching?) • being sent home from school almost daily since Sept with c/o stomachaches and/or breathing problems • Fussy about food, smells, textures; perfectionistic about work, checks locks x2 • worries about “everything” Where to begin? • Assessment issues • Treatment issues The questionable outcome: the “treated” anxiety disorder • Children referred to clinic on good doses of SSRI’s, chronically • Hx of Panic, Sep Anx, GAD or social phobia • Essentially free of anxiety symptoms now • But don’t attend school, don’t function in community, have no anxiety tolerance • Unmotivated to move forward because they are “comfortable” and intolerant of any “discomfort” such as going out of the house -- & especially intolerant of CBT! Functional Outcomes • Adult data suggests that for panic disorder, although medication reduces symptoms more rapidly, functional outcome is superior for CBT, 2 years later • Competing goals? The “goal” of medication is to take symptoms away The goal of CBT is to learn to tolerate and cope with symptoms • Be sure that medication is prescribed and evaluated with functional outcomes in mind What is the Goal of Treatment? • Elimination of anxiety symptoms? • Or Reduction of symptoms to match coping level, with resultant ability to function • Then: Reduction of medication with upwards titration of skills • Risks of accepting the goal of eliminating anxiety? • 1. Failure to achieve goal • 2. If achieve elimination of anxiety a) they don’t developing coping skills b) amotivational side effects Solutions? • Always use the psychoeducational model - “Anxiety is natural and self-protective” - “However, those with sensitive body alarm systems AND a talent for creative worrying develop excessive anxiety and avoidance” - Need coping skills lifelong - Medication can reduce alarm sensitivity and reduce intensity of catastrophic worrying - Taper medication very slowly Role of Medications in this Model • Reset “panic alarm” (goes off less easily) • Calm physiological sensations (turn down the volume on the alarm) • Reduce intensity of cognitive worry • Regulate serotonergic, noradrenergic, gabaergic, glutamatergic systems etc. Take Home Message #1: SSRIs Effective in Anxiety Disorders • OCD: sufficient evidence for labelling in US (sertraline, fluoxetine, fluvoxamine) (2 DBPC trial each with endpoint 25-40% decrease in YBOCS with about 50% responding) • GAD/Mixed anxiety disorders: One +ve DBPC trial for each of the above • Social phobia (Parox); selective mutism (Fluox) • Placebo effect lower in anxiety disorders • In 1997 Emslie MDD fluoxetine study if control for anxiety, no effect for depression (CDER 2001) Other medications • Buspirone – limited older research but maybe effective, fewer behavioral SE; may avoid activation in bipolars • Benzodiazepines • – clonazepam: one RCT in adolescent panic, irritability is a limiting side effect; - alprazolam – limited data in school refusal • Trazodone – low dose, adjunctive for sleep • SNRI – not effective in 2 good GAD trials Walkup at al NEJM 2001: Fluvoxamine & Anxiety • Placebo-controlled trial total N=128 • Mixed Current Anxiety Dx (51-69% for each) GAD, Sep Anx , Soc Phobia • Relatively low comorbidity: about 15% current or past ADHD; 5-6% current or past ODD; 5% past MDD • Mean medication dose 2.9 mg/kg; mean last dose 4.0 mg/kg fluvoxamine • (RUPP at NIMH) Walkup et al NEJM 344: 1279-1285, 2001 Mean scores on PARS (<10=mild) Figure 3. Cumulative Response Rates on the CGI-Improvement 76% (48/63) of fluvoxamine had a response; 29% (19/65) of placebo (p<.001) Rynn et al – AJP Dec 2001 • Placebo controlled trial of sertraline, 25 mg first week, 50 mg weeks 2-9 • Ages 5-17; total 22 patients • Primary Diagnosis GAD, Ham-Anxiety Score > 16, no comorbid non-anxietyAxis I • No other Rx offered but able to continue usual psychoRx if stable for 3 mos • Huge effect size in small study* PC Trial of Sertraline in GAD Rynn et al Am J Psych (p<0.001) Additional findings • Fluoxetine mixed anxiety study (Birmaher et al 2003, JAACAP) 61% responded to fluoxetine 20 mg and 35% to placebo • Extension of RUPP fluvoxamine study (Walkup at al JCAP 2002) found gains maintained, also did well if switched to fluoxetine from placebo “Psychiatric” effects of SSRIs 10-25% rate in children • “emotional lability” • Aggression/hostility • Agitation/akathisia/activation • Suicidal ideation & self-harm • Disinhibition • Motor hyperactivity (Fluvoxamine anxiety trial 27% vs 10% placebo) • Later: sexual, amotivational Side effects to mention to family (plus give handout*) • Behavioral activation • Disinhibition • Increased motor activity/tics • Obsessive suicidal thoughts Be aware of: • Sexual side effects • Amotivational syndrome (later) *our handout mentioned behavioral, suicidal and bleeding side effects several years before labelling Dosing SSRIs in Anxiety • Start low in kids (lower and slower in anxiety) • Titrate with patient/family – phone • Slower titration reduces psychiatric adverse effects especially disinhibition • Slow titration for adaptation in social phobia • Low doses may work eg 50 mg Ser in GAD • Higher doses in OCD (eg 200 fluvoxamine) • If no response at all by 6 wk to 20 mg fluxetine or equivalent, increase to 30 mg then, if partial response, can increase to 40 mg • If no response at 8 wk (10 weeks OCD) switch? • Target dose 20-40 mg (100-200 mg Ser/Fluv) or lowest effective The family returns… • 2 weeks later: Good News – less intensity of worry, fewer complaints of stomach aches • BUT – a week after started, seems excitable, overactive, not sitting still, giddy at times, teacher has sent home a note that the child is very restless…… What could be going on? How would you assess? Differential Diagnosis of “Activated” side effects • Simple stimulation (caffeine-like): very brief, settles with low dose, time • Behavioral activation: increased motor activity, more giddy, few hours after meds (watch dose, often settles with time) • Hypomania/Mania – dramatic, hyperarousal, sleep disturbance, family history, persistent, extreme • Movement disorders: akathisia (often persists), choreiform (often settles) How long to continue? • The child is improving on lowered dose Tips on discontinuing medication (after 6 months to a year, try it!) • Careful preparation is essential • Remind them that their body alarm system is sensitive so we’ll go very slowly – but this is an opportunity to practice skills • Remind them that discontinuation effects (dizzy, nausea, funny pains and shooting sensations, sleep disturbance) will pass • Slow titration downward (eg 5-10 mg/month) • Open & empty out capsules, split pills • Accompany with “booster” CBT training The Promise of Medications • Prevent psychosocial impairments • Prevent the personality “shaping” which anxiety achieves • Improved academic output • Prevent secondary depression • Positive impact on family dynamics • Available when CBT is not Challenges in Prescribing • Anxiety disorders are common (up to 10% of kids), chronic and recurrent • Thresholds for treatment? • Behavioral adverse effects especially in younger kids; sexual side effects in teens • Trouble discontinuing (sensitive to discontinuation effects: anxiety sensitivity) Ideal Approach • See medication as one of many “Tools” • Always combine medications with coping strategies which increase self-efficacy • “Prescribe” behavioral and coping strategies (including exercise, sleep hygiene, exposure practice) as “medically necessary” too: write them on a prescription pad Detecting clinical trends: Guess what we are using? • Quetiapine for anxiety & sleep (low dose) • (olanzepine less so due to weight gain) • Risperidone in OCD or anxiety/Tourette’s • Valproate in anxiety with rages, mood instability • * Lamotrigine in adolescents with OCD, panic, mood instability (watch for this class) • Anything else?